Apollo Endosurgery Announces Presentation of Mortality and Inpatient Costs of Revisional Bariatric Surgery

AUSTIN, Texas--(BUSINESS WIRE)-- Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced the presentation of the study results “Mortality and Inpatient Costs of Revisional Bariatric Surgery: A Nationwide Analysis” at Digestive and Disease Week in Washington, DC.

The presentation reported a retrospective cohort analysis of a Nationwide Inpatient Sample (NIS) discharge data on adult patients who had a principle diagnosis indicating a revisional bariatric surgery. The primary outcome reviewed in the study was mortality following revisional surgery. Secondary outcomes were cost, length of hospital and intensive care stay.

Key data reported from 14,280 patients who underwent inpatient revisional bariatric surgeries include:

  • Post-operative inpatient mortality was 2.1% (290 patients)
  • Length of hospital stay was 5.4 days
  • Mean cost per patient was $65,836
  • 3.3% of patients required intensive care stay, and of those, there was a 25% mortality rate

“Revisional bariatric surgeries increased from 6% of all bariatric procedures in 2011 to 13% in 2015. Previously published data based solely on a self-reported registry suggest a mortality rate of approximately 0.12 – 0.21%. In our study, which was based on inpatient billing data, the early post-operative inpatient mortality rate for revisional bariatric surgery was 2.1% - significantly higher than previously reported,” said Violeta B. Popov MD, Ph.D., lead author of the study and Assistant Professor, Department of Medicine at NYU Langone Health. “Alternatively, evidence demonstrates an endoscopic approach to bariatric surgical revisions is a safe, effective and clinically meaningful option for patients that should be considered before surgery.”

“Revision of bariatric surgery has increased, and we expect this will continue. An endoscopic approach to bariatric revision based on flexible endoscopic suturing using OverStitch™ demonstrates clinically meaningful benefits, at a much lower cost, and without the increased risks of surgery,” said Todd Newton, CEO of Apollo Endosurgery.

About OverStitch™

The OverStitch endoscopic suturing system enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures from a flexible endoscope. This new technology enables a secure approximation of tissue endoscopically and a wide range of less invasive solutions for physicians who treat defects in both the upper and lower GI tract of their patients. Additionally, physicians are leveraging endoscopic suturing to perform a variety of advanced bariatric procedures. For more information regarding OverStitch go to: www.apolloendo.com.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal conditions. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the ORBERA® Intragastric Balloon, and the LAP-BAND® Adjustable Gastric Banding System.

Apollo’s common stock is traded on Nasdaq Global Market under the symbol "APEN." For more information regarding Apollo, go to: www.apolloendo.com.

© 2018 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: reports of adverse events related to our products, developments in medical technology, regulatory approvals and extensive regulatory oversight by the FDA or other regulatory bodies, unfavorable media coverage related to our products or related procedures, reimbursement decisions by private or government payors, physician adoption and recommendations of procedures utilizing our products and other factors detailed from time to time in the reports Apollo files with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2017 and its Form 10-Q for the three months ended March 31, 2018. Copies of reports filed with the SEC are posted on Apollo’s website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.



Apollo Endosurgery, Inc.
Media Contact:
Jen Cook, 512-279-5158
Investor Contacts:
Stefanie Cavanaugh, 512-279-5100
Chief Financial Officer
The Ruth Group
Lee Roth, 646-536-7000


Source: Apollo Endosurgery, Inc.

Back to news